Schwartz Investment Counsel Inc. Buys 223,500 Shares of Haemonetics Corporation (NYSE:HAE)

Schwartz Investment Counsel Inc. raised its holdings in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 148.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 374,500 shares of the medical instruments supplier's stock after acquiring an additional 223,500 shares during the quarter. Schwartz Investment Counsel Inc. owned approximately 0.75% of Haemonetics worth $23,799,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Boston Trust Walden Corp raised its holdings in Haemonetics by 22.1% during the first quarter. Boston Trust Walden Corp now owns 1,118,331 shares of the medical instruments supplier's stock valued at $71,070,000 after acquiring an additional 202,609 shares during the period. Cardinal Capital Management raised its holdings in Haemonetics by 8.4% during the first quarter. Cardinal Capital Management now owns 19,815 shares of the medical instruments supplier's stock valued at $1,259,000 after acquiring an additional 1,531 shares during the period. Fort Washington Investment Advisors Inc. OH raised its holdings in Haemonetics by 88.6% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 517,086 shares of the medical instruments supplier's stock valued at $32,861,000 after acquiring an additional 242,956 shares during the period. SG Americas Securities LLC raised its holdings in Haemonetics by 510.9% during the first quarter. SG Americas Securities LLC now owns 10,580 shares of the medical instruments supplier's stock valued at $672,000 after acquiring an additional 8,848 shares during the period. Finally, QV Investors Inc. bought a new stake in Haemonetics during the first quarter valued at about $714,000. 99.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. JMP Securities reaffirmed a "market outperform" rating and issued a $100.00 target price on shares of Haemonetics in a report on Tuesday, May 20th. Baird R W raised Haemonetics to a "strong-buy" rating in a report on Wednesday. Wall Street Zen cut Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. Robert W. Baird assumed coverage on Haemonetics in a report on Thursday. They issued an "outperform" rating and a $87.00 target price on the stock. Finally, Raymond James Financial reaffirmed a "strong-buy" rating and issued a $105.00 target price (down from $115.00) on shares of Haemonetics in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $96.80.

Haemonetics Trading Down 1.1%

Shares of NYSE HAE opened at $73.97 on Friday. The business's 50 day moving average is $67.81 and its two-hundred day moving average is $68.27. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.62 and a quick ratio of 0.99. Haemonetics Corporation has a 1-year low of $55.30 and a 1-year high of $94.99. The stock has a market capitalization of $3.55 billion, a P/E ratio of 22.35, a PEG ratio of 1.21 and a beta of 0.36.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.02. The company had revenue of $330.60 million for the quarter, compared to analysts' expectations of $329.38 million. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The firm's revenue for the quarter was down 3.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.90 earnings per share. As a group, research analysts expect that Haemonetics Corporation will post 4.55 EPS for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.